Alberto Giuseppe Agostara, Laura Roazzi, Federica Villa, Rebecca Romano', Daniele Piscazzi, Francesca Martinelli, Gabriele Ciarlo, Sara Oresti, Francesca Travaglini, Alessandro Marando, Andrea Sartore-Bianchi, Laura Giannetta, Giulio Cerea, Salvatore Siena, Elio Gregory Pizzutilo, Diego Signorelli
INTRODUCTION: Immune-checkpoint inhibitors (IO) have significantly improved outcomes of patients with non-oncogene-addicted non-small cell lung cancer (NSCLC), becoming the first-line agents for advanced disease. However, resistance remains a significant clinical challenge, limiting their effectiveness. AREAS COVERED: Hereby, we addressed standard and innovative therapeutic approaches for NSCLC patients experiencing progression after IO treatment, discussing the emerging resistance mechanisms and the ongoing efforts to overcome them...
October 10, 2023: Expert Review of Respiratory Medicine